

# EXECUTIVE SUMMARY

First nine months 2022




## Main figures €Mn

REVENUE	EBITDA	EBIT
575.5 (+24%)	173.9 (+25%)	156.8 (+27%)
Net profit	Capex	Net debt
121.5 (+23%)	18.5 (-16%)	25.9

**2023 operating revenue guidance:**  
**Low-double-digit negative growth vs 2022**  
**Positive growth of between 5% and 10% vs 2021**


ROVI presents Glycopepton Biotech, S.L., a joint venture with Càrniques Celrà, S.L. and Grupo Empresarial Costa, S.L., that involves the construction of a facility which will produce heparins, in order to be present in all the manufacturing phases of LMWH

## Operating revenue €Mn



■ CMO business ■ Specialty pharmaceutical business

## Specialty pharma business €Mn



**Heparin franchise\*** €200.6 (+11%) 35% of operating revenue

**LMWH** €195.1 (+11%)

### Bemiparin sales

€75.8m (-12%)

Spain  
€50.4m

International  
€25.4m

### Enoxaparin sales

€119.2m (+33%)

✓ Directly marketed in Germany, UK, Italy, Portugal, Spain and Poland.

✓ Approved in 26 countries in Europe and 31 in RoW.


✓ Launched in 38 countries.

\* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


## CMO business €Mn

Total €267.9m (+49%)


## Gross profit €Mn



## SG&A expenses €Mn



## EBITDA €Mn



## R&D expenses €Mn €16.2 -15%


Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Phase III	<ul style="list-style-type: none"> <li>✓ Approved in Europe</li> <li>✓ In approval process in USA</li> </ul>
Letrozole ISM® Long acting Letrozole	Breast Cancer	Phase I	Phase I started in November 2017
Risperidone, quarterly	Schizophrenia	Non-Clinical	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform



## Net Profit €Mn



## News flow

### SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

### CMO

- ✓ New contracts to be announced
- ✓ Evolution of Moderna's vaccine manufacturing.

### ISM® Technology Platform

- ✓ Launch of Okedi® in Europe (already launched in Germany, UK and Spain)
- ✓ Marketing authorization for Risvan® in USA
- ✓ Discussions with FDA initiated to review Letrozole ISM® phase I results as well as next steps